Eledon Pharmaceuticals, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 |
|---|---|---|
| Operating expenses | $83.3M | $70.6M |
| Cash from operations | -$62.3M | -$47.3M |
| Impairments | — | $0 |
| Total assets | $169.0M | $177.4M |
| Total liabilities | $32.2M | $59.3M |
| Total debt | $0 | $0 |
Shares outstanding 77.2M · Free float 76.2%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.